Cargando…
Immunotherapy for Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is characterized by extensive tumor heterogeneity at both the pathologic and molecular levels, particularly accelerated aggressiveness, and terrible metastasis. It is responsible for the increased mortality of breast cancer patients. Due to the negative expressio...
Autores principales: | Cao, Yifeng, Chen, Chuyang, Tao, Yi, Lin, Weifeng, Wang, Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705248/ https://www.ncbi.nlm.nih.gov/pubmed/34959285 http://dx.doi.org/10.3390/pharmaceutics13122003 |
Ejemplares similares
-
Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023) -
Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021) -
Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022) -
The clinical promise of immunotherapy in triple-negative breast cancer
por: Vikas, Praveen, et al.
Publicado: (2018) -
Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
por: Wesolowski, Jakub, et al.
Publicado: (2022)